Fragments vs DsbA: Towards a Chemical Probe

Key Takeaways

• DsbA catalyzes disulfide bonds, essential for bacterial virulence
• Fragment screens uncovered a cryptic pocket hidden within DsbA
• Optimized analogs achieved low‑micromolar binding and functional inhibition
• Direct‑to‑biology flow chemistry accelerated synthesis of 92 crude candidates
• Results highlight dynamic proteins as sources of druggable cryptic sites

Pulse Analysis

Antibiotic resistance is reshaping the pharmaceutical landscape, prompting scientists to explore anti‑virulence approaches that disarm pathogens rather than kill them outright. The periplasmic oxidoreductase DsbA is indispensable for forming disulfide bonds in over 300 bacterial proteins, many of which are linked to resistance mechanisms and host colonization. By inhibiting DsbA, researchers aim to blunt Escherichia coli’s infectivity without imposing the selective pressure that drives classic resistance, positioning the enzyme as a high‑value target for next‑generation antimicrobials.

Fragment‑based drug discovery (FBDD) has proved especially useful for challenging targets lacking deep binding grooves. Early fragment screens against DsbA revealed two dozen hits in its shallow hydrophobic groove and, intriguingly, a few that accessed a concealed cryptic pocket. Structural studies showed the pocket is fully enclosed, yet protein dynamics allow transient openings that let fragments slip inside, preferentially binding the oxidized, active form of DsbA. Although the best initial fragments bound with only ~150 µM affinity, the research team engineered compounds that protrude beyond the pocket, achieving mid‑micromolar potency (compound 13) and, after a rapid‑synthesis, direct‑to‑biology campaign, low‑micromolar inhibition (compound 17) that also reduced bacterial swarming in functional assays.

These advances underscore the strategic value of cryptic sites in drug design. Even when pockets are small and seemingly undruggable, they can serve as footholds for iterative chemistry that expands molecular interactions and improves potency. The demonstrated workflow—combining crystallography, NMR, SPR, HDX, and automated flow chemistry—offers a blueprint for accelerating probe development against other dynamic bacterial proteins. Continued optimization may yield a robust chemical probe for DsbA, paving the way for anti‑virulence therapeutics that complement, rather than replace, traditional antibiotics.